Effect of early two-dose measles vaccination on childhood mortality and modification by maternal measles antibody in Guinea-Bissau, West Africa: A single-centre open-label randomised controlled trial

BACKGROUND: Early 2-dose measles vaccine (MV) at 4 and 9 months of age vs. the WHO strategy of MV at 9 months of age reduced all-cause child mortality in a previous trial. We aimed to test two hypotheses: 1) a 2-dose strategy reduces child mortality between 4 and 60 months of age by 30%; 2) receiving early MV at 4 months in the presence versus absence of maternal measles antibodies (MatAb) reduces child mortality by 35%. METHODS: Single-centre open-label community-based randomised controlled trial in Guinea-Bissau, with 2:1 block-randomisation by sex to a 2-dose (4 + 9 months) vs. 1-dose (9 months) MV strategy. Healthy children were eligible 4 weeks after the 3rd diphtheria-tetanus-pertussis-containing vaccine. Before randomisation a blood sample was collected to determine MatAb level. The primary outcome was all-cause mortality. Hazard ratios (HR) were derived from Cox regression in the per protocol population. We tested for interactions with national campaigns with oral polio vaccine (C-OPV). Trial registration: NCT01486355. FINDINGS: Between August 2011-April 17th 2015, 6,636 children were enroled, 6,598[n(2-dose)=4,397; n(1-dose)=2,201] were included in the analysis of the primary outcome, The HR(2-dose/1-dose) between 4 and 60 months was 1.38 (95%CI: 0.92–2.06) [deaths: n(2-dose)=90; n(1-dose)=33]. Before the 9-month MV and the HR(1-dose/no dose) was 0.94 (0.45–1.96) [deaths: n(2-dose)=21; n(1-dose)=11]. The HR(2-dose/1-dose) was 0.81 (0.29–2.22) for children, who received no C-OPV [deaths/children: n(2-dose)=10/2,801; n(1-dose)=6/1,365], and 4.73 (1.44–15.6) for children, who received C-OPV before and after enrolment (p for interaction=0.027) [deaths/children: n(2-dose)=27/1,602; n(1-dose)=3/837]. In the 2-dose group receiving early MV at 4 months, mortality was 50% (20–68%) lower for those vaccinated in the presence of MatAb vs. the absence of MatAb [deaths/children: n(MatAb)=51/3,132; n(noMatAb)=31/1,028]. INTERPRETATION: The main result contrasts with previous findings but may, though based on a small number of events, be explained by frequent OPV campaigns that reduced the mortality rate, but apparently interacted negatively with early MV. The beneficial non-specific effects of MV in the presence of MatAb should be investigated further. FUNDING: 10.13039/501100000781ERC, Danish National Research Foundation, the Danish Council for Development Research, Ministry of Foreign Affairs, Novo Nordisk Foundation, European Union and the Lundbeck Foundation.